Expression of CD44v6 correlates with cell proliferation and cellular atypia in urothelial carcinoma cell lines 5637 and HT1197.
CD44 comprises a family of membrane adhesion molecules encoded by a single gene and diversified by alternative splicing and extensive posttranslational modifications. Alterations of CD44 expression patterns are linked to tumour invasion and formation of metastases. However, CD44 expression and its relation to the biological properties of tumours vary depending on the tumour type and origin. In transitional cell carcinoma of the urinary bladder, low CD44 expression is linked to enhanced tumour aggressiveness. We studied CD44 expression in two urothelial cancer cell lines, HT1197 and 5637. CD44s and a v6 variable exon-containing splice variants were detected in both cell lines by reverse transcription-PCR and by commercially available monoclonal antibodies. In both cell lines, Western blot analysis detected immunoreactive proteins with approximate sizes 70-85 kD, 95-110 kD, and 120-140 kD with CD44v6 antibody and weak bands with size 70-98 kD with CD44s antibody. At the cellular level, the pattern of CD44 immunoreactivity correlated with a lower level of cell differentiation and a higher degree of cell proliferation. In HT1197 cells, the CD44v6 was detected predominantly in small proliferating cells and in large multinuclear atypical cells. CD44s and CD44v6 displayed low immunoreactivity in HT1197 cells with a higher degree of epithelial differentiation. The 5637 cells expressed CD44v6 strongly and CD44s weakly. We conclude that CD44v6 expression correlates with a higher proliferative activity and with a stem cell-like phenotype in both cell lines and with cellular atypia in HT1197 cells.
Kuncová
J
J
Clinical Department of Urology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic.
Kostrouch
Z
Z
Viale
M
M
Revoltella
R
R
Mandys
V
V
D017398:Alternative Splicing / Q000235:genetics / Q000276:immunology; D002295:Carcinoma, Transitional Cell / Q000378:metabolism* / Q000473:pathology* / Q000503:physiopathology; D002454:Cell Differentiation / Q000235:genetics / Q000276:immunology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D048430:Cell Shape / Q000235:genetics / Q000276:immunology; D002471:Cell Transformation, Neoplastic / Q000276:immunology / Q000378:metabolism; D006023:Glycoproteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D018960:Hyaluronan Receptors / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D007150:Immunohistochemistry; D009361:Neoplasm Invasiveness / Q000276:immunology; D020033:Protein Isoforms / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D001749:Urinary Bladder Neoplasms / Q000378:metabolism* / Q000473:pathology* / Q000503:physiopathology; D019459:Urothelium / Q000378:metabolism* / Q000473:pathology*
C112697:CD44v6 antigen; D006023:Glycoproteins; D018960:Hyaluronan Receptors; D020033:Protein Isoforms